Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Västra Hamnen Market Focus: Gabather: Eager to start the TOTEMS study

Gabather
  • A TOTEMS study article published in Frontiers in Psychiatry
  • The exercise of TO 7 warrants provides some financial relief
  • We keep our fair value of SEK 0.092 per share

Gabather's reported figures in its recent Q3 report were close to our estimates, however with a weaker cash position. The exercise of TO 7 warrants will help alleviate this, for now. Over the autumn Gabather has been scientifically validated, both by presenting a poster at the Society for Neuroscience Annual Meeting and by a published article in Frontiers in Psychiatry. Looking ahead, we expect the first patient to be treated in the TOTEMS phase II clinical trial around the turn of the year. We make only minor adjustments to our model and maintain our fair value of SEK 0.092 per share.

The full report is available here.

About Market Focus


The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.